Liver transplantation for Budd‐Chiari syndrome: When is it really necessary?
Sarwa Darwish Murad, Patrick S. Kamath – 30 January 2008
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
Jacob Alexander, James D. Lord, Matthew M. Yeh, Carlos Cuevas, Ramasamy Bakthavatsalam, Kris V. Kowdley – 30 January 2008 – Orthotopic liver transplantation (OLT) is the only effective treatment for end‐stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC. We performed a retrospective analysis of 69 consecutive patients who underwent a first OLT for PSC over a 14‐year period.
Transient portocaval shunt for a small‐for‐size graft in living donor liver transplantation
Toru Ikegami, Satoru Imura, Yusuke Arakawa, Mitsuo Shimada – 30 January 2008
Addictive behavior after solid organ transplantation: What do we know already and what do we need to know?
Santiago Tome, Adnan Said, Michael R. Lucey – 30 January 2008
Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction
Ashokkumar Jain, Rajeev Sharma, Charlotte Ryan, Georgious Tsoulfas, Mark Orloff, Peter Abt, Randeep Kashyap, Pam Batzold, Lisa Sauberman, Saman Safadjou, Maureen Graham, Adel Bozorgzadeh – 30 January 2008 – With the current immunosuppressive regimens, graft loss secondary to immunological reasons after successful liver transplantation is a rarity; acute rejections, however, do occur, with the majority of them being steroid‐responsive.
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
Evangelos Cholongitas, Vibhakorn Shusang, George V. Papatheodoridis, Laura Marelli, Pinelopi Manousou, Nancy Rolando, David Patch, Keith Rolles, Brian Davidson, Andrew K. Burroughs – 30 January 2008 – Liver transplantation (LT) is the only therapeutic option for end‐stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr).
Insulin resistance, hepatitis c, and liver transplantation
Mazen Alsatie, Prashant Pandya, Naga P. Chalasani – 30 January 2008
Donor‐transmitted malignancy confirmed by quantitative fluorescence polymerase chain reaction genotype analysis: A rare indication for liver retransplantation
Katie Snape, Louise Izatt, Paul Ross, David Ellis, Kathy Mann, John O'Grady – 30 January 2008
Recurrence of hepatocellular carcinoma after liver transplantation presenting with massive intrahepatic bleeding
Matteo Donadon, Alessandro Giacomoni, Andrea Lauterio, Abdallah Slim, Vincenzo Pirotta, Iacopo Mangoni, Luciano De Carlis – 30 January 2008
A randomized, prospective, pharmacoeconomic trial of neoral 2‐hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients
Surendra Shenoy, Karen L. Hardinger, Jeffrey Crippin, Kevin Korenblat, Mauricio Lisker‐Melman, Jeffrey A. Lowell, William Chapman – 30 January 2008 – Two‐hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)‐based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of cyclosporine A (CsA) monitored by C2 levels versus FK monitored by trough levels in de novo liver transplant recipients.